|
New Indications
- Atezolizumab (Tecentriq), in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
- Ibrutinib (Imbruvica) is now indicated for the treatment of Waldenström’s macroglobulinaemia in adults: as a single agent in patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy; or in combination with rituximab. Ibrutinib, as a single agent, or in combination with obinutuzumab, is now indicated for the treatment of previously untreated chronic lymphocytic leukaemia/small lymphocytic leukemia (CLL/SLL) in adults with or without deletion 17p. Ibrutinib, as a single agent, or in combination with bendamustine and rituximab, is now indicated for the treatment of CLL/SLL in adults with or without deletion 17p who have received at least one prior therapy.
- Pembrolizumab (Keytruda) is now indicated as monotherapy for the first-line treatment of patients with non-small cell lung cancer expressing PD-L1 (tumour proportion score ≥ 1%), with no EGFR or ALK genomic tumour aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
- Ribociclib (Kisqali) is now indicated for the treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant, as initial endocrine-based therapy or following prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone agonist.
|
|
|
New Contraindications
- Diphenhydramine HCl/paracetamol (Mersynonight Night Time Pain Relief) is now contraindicated in severe hepatocellular insufficiency.
- Efavirenz (Stocrin) is now contraindicated with elbasvir/grazoprevir.
- Levothyroxine sodium (Oroxine, Eutroxsig) is now contraindicated in acute myocarditis and acute pancarditis.
|
|
|
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.
|
|
|
|
|
|
|
|
|
